Batch record review and product release: from completed manufacturing to authorized supply

1. Start with a defined batch and market

A completed production order is not an authorization to sell. Establish the exact product, strength, dosage form, manufacturing and packaging batch relationship, quantity, destination market and review scope. Confirm the authorized site, formula, process, specifications and artwork applicable when the batch was made.

This guide addresses routine finished medicinal-product batches. Sterile products, biologics, clinical-trial supplies, radiopharmaceuticals and parametric or real-time release require additional specialist controls. Do not extrapolate a conventional finished-product checklist into permission to omit testing.

2. Separate preparation, independent review and disposition

Production should review the executed record for completeness, explain discrepancies and provide supporting evidence before handover. QC reviews the laboratory package. Quality evaluates the integrated batch history and the person authorized under applicable law and the site quality system records final disposition. Define deputies and outsourced responsibilities in advance.

Commercial urgency does not confer release authority. A certificate of analysis reports approved analytical results; it is not, by itself, proof that manufacturing, packaging, deviations and regulatory conditions are acceptable.

3. Build a review package that can reconstruct the batch

Use a controlled index linking the batch manufacturing record, packaging record, material genealogy, IPC results, laboratory package, relevant electronic data, equipment records and investigations. Reconcile issued pages and attachments. Identify which system holds each original record and how paper and electronic records connect.

Review chronology as well as signatures: dispensing, processing, sampling, cleaning, holds and packaging should form a credible sequence. Missing contemporaneous evidence must be assessed as a data or quality issue. A late explanatory entry should be clearly identified and supported; never backdate or recreate an observation as if it were original.

4. Review what actually happened in manufacture

Compare recorded parameters and sequence with effective instructions and validated ranges. Check calculations, material lots and release status, actual additions, equipment identity and hold times. Review relevant cleaning, maintenance, calibration and utility events during the batch—not merely the equipment's current status.

A power interruption or overdue calibration may affect only part of the batch, or several batches. Establish the actual time window, equipment and product exposure. Passing finished-product results do not automatically resolve an uncontrolled process or incomplete evidence.

5. Reconcile yield, printed materials and market identity

Verify stage yields and quantity reconciliation using consistent units and approved limits. Account for samples, rejects, returns and destruction. Investigate unexplained differences instead of adjusting entries to achieve a preferred result.

For packaging, verify artwork version, strength, language, market, batch coding, expiry and line clearance. A perfectly balanced carton count cannot prove that the correct carton was used. Conversely, a numerically small discrepancy may still indicate a mix-up requiring investigation.

6. Review laboratory evidence beyond the certificate

Confirm that required tests are complete under approved methods and specifications, with valid sampling and traceable sample custody. Review original data, calculations, relevant integrations, system suitability and critical audit trails under the approved review procedure. Include subcontracted testing and any required supporting records.

Preserve the original OOS result and investigate scientifically. A passing retest alone does not invalidate it. OOT or otherwise atypical results can require assessment even when within specification. Do not average away a failure or select only favorable results.

7. Resolve exceptions at the batch level

Reconcile the batch record against deviation, OOS, maintenance, environmental and change-control registers. Assess cumulative effects and other potentially affected batches. Confirm whether implementation or regulatory conditions were met before a change was used.

Distinguish investigation conclusions, immediate correction and long-term prevention. An investigation affecting batch acceptability must reach a scientifically supported disposition before release. Some preventive actions or later effectiveness checks may remain open only where permitted by applicable requirements and the approved quality system, with documented rationale, interim controls, owners and deadlines. This is not a general permission for conditional release.

8. Make release, hold or rejection explicit

Maintain a hold when required evidence is incomplete or material uncertainty remains. Release requires all applicable prerequisites and authorized sign-off in the controlled system. Rejection requires an approved disposition and protection against accidental re-entry into usable stock. The reviewer should be able to explain the evidence behind the decision, not merely show checked boxes.

Record batch identity, quantity and market scope, decision date, authority, key evidence and any justified commitments. Ensure the warehouse receives an unambiguous status change. A change in an uncontrolled spreadsheet must not trigger dispatch.

9. Work through realistic review cases

The following are illustrative training scenarios, not reports of named companies. Case A: assay passes but a compression interruption has no documented assessment. Keep the batch on hold while reconstructing the event from reliable records, reviewing process conditions and assessing impact; the assay result does not close the issue.

Case B: one carton version is obsolete for the intended market. Segregate and assess actual affected units, label compliance and traceability. Any proposed repacking needs authorized instructions, regulatory assessment where applicable and subsequent review—not an informal warehouse correction.

Case C: an investigation supports batch acceptability, but an equipment redesign CAPA will take three months. Establish whether any pre-release action remains outstanding and whether interim controls are effective. The authorized decision must comply with local requirements; open long-term CAPA is neither an automatic release ban nor an automatic exemption.

Case D: packaging reconciliation shows 10,000 cartons issued, 9,800 used, 150 returned and 40 destroyed. Ten are unexplained. Investigate the discrepancy and potential mix-up rather than inventing a destruction entry. Decide the batch impact using actual evidence.

10. Apply the correct release framework in Africa and India

Africa has no single national batch-release law. Confirm the operating country's regulator, licence conditions, destination-market requirements and the recognized responsible person. WHO GMP is an important technical reference, not a substitute for local legal authority.

For India, apply the Drugs Rules, relevant revised Schedule M provisions and subsequent applicable amendments, licences and product authorizations. EU QP certification is a distinct framework and should not be represented as the legal basis for ordinary non-EU batches merely because an EU guidance document was consulted. Confirm EU requirements when the actual manufacturing/import and destination arrangements bring them into scope.

11. Control storage, dispatch and later information

Review finished-product storage history and relevant excursions. Complete required retention-sample and stability commitments. Keep physical and electronic dispatch blocks until authorized release is communicated and acknowledged.

Preserve distribution traceability and a defined escalation path if new information arises after release. Later stability failures, supplier alerts or data-integrity findings may require assessment of distributed batches and recall or regulatory reporting under applicable procedures. Release is a decision based on evidence at a point in time, not immunity from later review.

12. Improve review flow without lowering standards

Use a practical review queue showing batch, package completeness, accountable reviewer, open issues and target dates. Encourage review during execution where appropriate, while retaining the required final integrated review. Track first-pass completeness, recurring documentation errors and the age and causes of review delays.

These are suggested management practices, not universal prescribed deadlines. Measure how reliably problems are resolved, not just how quickly batches are released. The companion workbook organizes evidence and actions; it is not a validated GxP system, electronic signature or release authorization.